Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sylvia Mohen

Neurology New York, NY Medical Doctor

NPI 1962790907 CMS profile 1311911

1035 Park Ave, New York, NY 10028

Open in the dashboard

General payments

$35,599

1,959 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sylvia Mohen of New York, NY is reported in the CMS Open Payments database as having received $35,599 across 1,959 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,345 302
2024 General $6,777 372
2023 General $5,737 327
2022 General $5,292 300
2021 General $5,719 312
2020 General $3,307 196
2019 General $2,422 150

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sylvia Mohen
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Sylvia Mohen were reported at $6,345. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Sylvia Mohen Neurology median Middle half National median
2019 $2,422 $474 $118–$2,177 $163
2020 $3,307 $367 $82–$2,309 $114
2021 $5,719 $438 $104–$2,547 $132
2022 $5,292 $442 $103–$2,388 $149
2023 $5,737 $464 $119–$2,312 $160
2024 $6,777 $468 $119–$2,323 $164
2025 $6,345 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $6,260 337 payments
  2. Teva Pharmaceuticals USA, Inc. $2,242 149 payments
  3. UCB, Inc. $2,105 111 payments
  4. Pfizer Inc. $1,923 118 payments
  5. Allergan Inc. $1,424 96 payments
  6. Harmony Biosciences LLC $1,385 60 payments
  7. SK Life Science, Inc. $1,297 77 payments
  8. Lilly USA, LLC $1,205 76 payments
  9. Amneal Pharmaceuticals LLC $1,175 62 payments
  10. US WorldMeds, LLC $1,095 37 payments
  11. Other $15,489 836 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $35,017 1,944 payments
  2. Education $562 14 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $19 1 payment
Products named General payments · program years 2019–2025
  1. UBRELVY Neuroscience $3,188 174 payments
  2. QULIPTA $2,710 142 payments
  3. NURTEC ODT Pain $1,874 115 payments
  4. NURTEC ODT Primary Care $1,523 94 payments
  5. Briviact $1,289 73 payments
  6. AIMOVIG $1,131 50 payments
  7. ZAVZPRET $1,058 68 payments
  8. VALTOCO $912 41 payments
  9. AJOVY $871 66 payments
  10. UBRELVY Neuroscience $805 51 payments
  11. Other $22,039 1,204 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

766

Median for Neurology: 833

Drug cost

$118,894

Median for Neurology: $202,670

Branded share of claims

26.5%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nurtec Odt Rimegepant Sulfate Brand 21 $33,216
Nuedexta Dextromethorphan Hbr/Quinidine Brand 15 $22,803
Aimovig Autoinjector Erenumab-Aooe Brand 25 $18,347
Qulipta Atogepant Brand 13 $14,284
Reyvow Lasmiditan Succinate Brand 15 $11,180
Emgality Pen Galcanezumab-Gnlm Brand 12 $8,528
Gabapentin Generic 96 $1,560
Memantine Hcl Er Memantine Hcl Brand 37 $1,285
Oxcarbazepine Generic 13 $1,279
Tizanidine Hcl Generic 30 $861

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$336,358

Of which drugs: $175,354

Medicare patients

244

Average age 73

Services billed

36,087

171 women, 73 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 64%
High blood pressure 63%
Ischemic heart disease 33%
Diabetes 32%
Osteoporosis 25%
Depression 23%
Cancer 19%
Chronic kidney disease 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 41 34,300 $171,058

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 43 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Gocovri
$584 — —
QULIPTA
$499 13 —
WAKIX
$433 — —
NURTEC ODT
$433 21 —
UBRELVY
$432 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 43 with Patron

Records

1,959 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record